Prescription Event Monitoring in Patients With Benign Prostatic Hyperplasia (BPH)

Secotex®: Prescription Event Monitoring in Patients With Benign Prostatic Hyperplasia (BPH)

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02244346

Enrollment

811

Registered

2014-09-19

Start date

2004-05-31

Completion date

Unknown

Last updated

2014-09-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostatic Hyperplasia

Brief summary

Study to evaluate the safety profile of Secotex® in the improvement of the symptoms of Benign Prostatic Hyperplasia in real clinical practice

Interventions

DRUGSecotex®

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

MALE

Healthy volunteers

Inclusion criteria

* Patients of any age with a diagnosis of symptomatic Benign Prostatic Hyperplasia (BPH) * Patients with symptoms, that according to physician require medical treatment to improve quality of life * Patients could be naive to treatment or could be on treatment with other drugs but have not responded adequately to treatment

Exclusion criteria

* Patients with known hypersensitivity to Tamsulosin, or any other component of the product * Patients with a history of orthostatic hypotension or severe liver failure

Design outcomes

Primary

Measure	Time frame
Number of patients with adverse events	up to 6 months

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026